

# NGS/CGP Liquid reimbursement journey in Latvia

Janis Silins, Market Access Head  
Roche Latvia

26.10.2022.

*Информация предназначена только для специалистов системы здравоохранения. Не для распространения. Информация носит исключительно научно-информационный характер, не является рекламой. Данная презентация была подготовлена при поддержке ТОО «Рош Казахстан»*

# Country Profile: Latvia



## General

- Population: 1,9 million
- The capital: Riga
- Official language: Latvian
- Official currency: EUR
- GDP growth (2021): +4,8 %
- GDP per capita (2021): 17'454 EUR

## Healthcare

- Centralized Public Healthcare system
- Universal coverage funded by general tax revenues;
- Gov. Health expenditure, % from Budget (2021): 12,5%
- Gov. Health expenditure out of GDP (2021): 5,3%
- Single Public payer National system (the National Health Service of Latvia)

# Challenges and Opportunities

## At the beginning of journey

### Opportunities

- Oncology as priority for healthcare
- 100% coverage of reimbursed services in oncology
- Increasing interest about PHC among the medical community
- Development of the National Oncology Plan 2017-2020

### Challenges

- Lack of NGS/CGP reimbursement
- Hotspot testing covered by patients (Out of Pocket) or pharma companies
- Low affordability for NGS/CGP services
- Lack of experience with NGS/CGP among the medical community
- Limited number of reimbursed MGTOs

## Decision making process



- Applied by **Medical institution** or **Associations of specialists**
- **HTA** process for services with budget impact above 70 000 EUR per year
- **Submission** of application and required information **to the National Health Service of Latvia (NHS)**
  
- The National Health Service of Latvia
  - Evaluation of submitted information
  - Calculations of the tariff and impact on budget
  
- Representatives of **the NHS and the Ministry of Health**
  - Alignment with public health priorities
  - Funding allocation for reimbursement of the new diagnostic service
  
- The National Health Service of Latvia
  - Define reimbursement tariffs, scope of service providers and cost coverage conditions



# Awareness towards PHC

## Educational and awareness activities about PHC and value of NGS/CGP testing in oncology

PHC Conference held by Ministry of Economics, May '19

PHC event at Parliament Health Committee, Jun '20

PHC Conference, Feb '20

Discussion on recommendations by EU Cancer Mission, Aug '20

### Oncology plan 2017-2020:

Defined costs for detection of tumor mutations (lung tumor, colorectal tumor, melanoma, etc.)

Law on the State Budget 2021 approved and designated **funding for NGS testing in Lung cancer** is allocated from excise tax increase for tobacco products  
Dec 2020

### Oncology plan 2022-2024 :

Defined strategy to expand NGS/CGP testing and reimbursement of MGTOs

2017-2018	2019-2020	2021	2022-2024
-----------	-----------	------	-----------

Launch of FMI services in Latvia  
Dec '16

NHS endorsement for inclusion of NGS/CGP testing for Lung cancer patients to the positive list of reimbursed services

**Negotiations on potential tariffs for NGS/CGP services for Lung cancer patients** between the NHS, the State Pathology center and Roche  
Jan-Mar '21

NGS reimbursement conditions in Ovarian and Colorectal cancer  
Jul '21

Further expansion of NGS/CGP Liquid funding conditions to the other dg groups according to the Oncology Plan 2022-2024

**Applications of F1CDx and F1LCDx submissions by the Association of Pathologists of Latvia**

Apr '19 (FMI CDx)  
May '20 (FMI Liquid)

**NGS/ CGP Liquid testing services for lung cancer included in the positive list of publicly reimbursed tariffs**  
Apr '21

**FoundationOne®Liquid (F1LCDx ) recognized as a winner of the tender for CGP Liquid testing of Lung cancer patients**  
Sep '21

# NGS/CGP testing reimbursement conditions

- **Actual** reimbursement conditions

Services	Payment and reimbursement conditions
Detection of mutations in oncology from a tissue sample with next-generation sequencing (NGS) technology	Paid to <b>Riga Eastern Clinical University Hospital</b> for <b>lung cancer, colorectal cancer and ovarian cancer</b> patients in order to decide on the further tactics of medication use, and for patients of other Oncology hospitals, if the examination was performed at Riga Eastern Clinical University Hospital
Comprehensive genomic profiling with next-generation sequencing (NGS) using liquid biopsy in oncology	Paid to <b>Riga Eastern Clinical University Hospital</b> only <b>with the conclusion of the Pulmonary Diseases Council</b> on the examination of patients with <b>lung cancer</b>

- **Planned** improvements according to the new National Oncology Plan 2022-2024:

- Expanding testing availability for other diagnoses
- Provide testing to 3227 patients (tissue) and 140 patients (liquid biopsy) per year

## Key take aways

- Importance of knowledge and expertise about NGS/CGP among health care professionals
- All stakeholders commitment on the value of PHC and NGS/CGP testing for patient centered healthcare development
- Long term strategy for successful introduction of new diagnostic services in oncology according to the international guidance and recommendations (ESMO, NCCN)
- Simultaneous development of NGS/CGP diagnostic capability and access to reimbursed MGTOs

**Doing now what patients need next**